Chronic myeloid leukemia (CML)

Sources of funding:

Research and Mode-of-Action: European Research Council Advanced Grant MaCChines 

Preclinical translation: European Research Council Proof-of-Concept

External Collaborations:

We performed advanced preclinical research on human cells with: 

Ljubljana University Medical Centre, Department of Haematology

• assoc. prof. Matjaž Sever MD, PhD
• Veronika Mikolič

Looking for clinical-stage partners with secured CRISPR licensing in the field of oncology

About the condition

Chronic myeloid leukemia (CML) is a myeloproliferative neoplastic disease.  

The diagnosis is based upon the genetic translocation between the t(9;22)(q34;q11.2), resulting in the formation of Philadelphia fusion chromosome, coding for BCR-ABL1 oncoprotein.  

This condition occurs during the person’s life and is not inherited. It has three phases; chronic phase (the majority of diagnosed cases), accelerated phase and blast phase.  

The life-long treatment relies on tyrosine kinase inhibitors (TKIs). Nearly 2% of patients develop point mutations, leading to the resistance to TKIs treatment. New solutions for treating cancer with genetic etiology are required.